New Microfluidic Device Revolutionizes Cancer Drug Screening

Scientists from National Taiwan University and the National Institutes of Applied Research of Taiwan have unveiled a groundbreaking microfluidic device designed to accelerate the process of drug screening for cancer treatments. This innovative technology generates precise drug gradients, significantly enhancing the reliability of multi-drug screening essential for personalized medicine.

Cancer continues to pose a formidable global health challenge, with the World Health Organization reporting approximately 20 million new cases and 9.7 million deaths in 2022. Projections indicate that the global incidence of cancer may exceed 35 million cases by 2050, underscoring an urgent need for effective and tailored treatment strategies. A significant barrier in effective cancer therapy is tumor heterogeneity, which leads to varied patient responses to drugs and the frequent emergence of drug resistance. This reality necessitates not only the development of new therapeutics but also the ability to swiftly evaluate optimal drug doses and combinations through dependable screening methods.

Traditional drug screening methods rely heavily on manual pipetting and serial dilution techniques. These approaches are labor-intensive and susceptible to cumulative errors, making them difficult to scale effectively. Although high-throughput screening systems have been developed to enhance testing capacity, they still encounter hurdles, particularly in generating the accurate concentration gradients required to ascertain crucial pharmacological parameters such as IC50 and Emax. Even minor dilution inaccuracies can distort drug-response curves, compromising their clinical relevance.

To overcome these challenges, researchers have created a high-throughput microfluidic device that can rapidly produce precise drug concentration gradients. This new system utilizes controlled laminar flow within microchannels, allowing for adjustments in concentration ratios through straightforward channel-length engineering. The result is a highly accurate gradient that remains stable across various flow rates, achieving a steady state within just 30 seconds.

Validation studies reported in the Chemical Engineering Journal demonstrate the device’s capabilities. Using BSA solutions and cancer drug assays, the device produced concentration gradients with deviations of less than 6% from theoretical values, significantly outperforming traditional manual dilution methods. When subjected to cytotoxicity tests, the effects of oxaliplatin on HCT-116 colorectal cancer cells revealed only a 2.45% difference in IC50 compared to conventional techniques. Furthermore, multi-drug screenings with 5-FU, oxaliplatin, and SN-38 showcased the device’s ability to consistently detect synergistic effects.

The design of the device’s outlet is compatible with standard 96-well plates, facilitating its integration into existing laboratory workflows. Researchers aim to apply this technology to patient-derived organoids, which could lead to advancements in precision oncology and personalized therapeutic strategies.

“By reducing labor, minimizing human error, and enabling rapid, reliable drug testing, this microfluidic platform significantly accelerates the cancer drug development pipeline,” states Chien-Fu Chen, Ph.D., co-corresponding author and a distinguished professor at the Institute of Applied Mechanics at National Taiwan University.

The implications of this research are profound, offering hope for more effective cancer treatments tailored to individual patient needs. As research continues, the potential for this microfluidic device to transform the landscape of cancer therapy remains promising. Further details can be found in the study published by Po-Hsun Chen et al. in the Chemical Engineering Journal (2025). For more information, refer to DOI: 10.1016/j.cej.2025.169510.